Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lynx1 Capital Management LP Insider Profile
11 Followers
Lynx1 Capital Management LP, Ten Percent Owner at TScan Therapeutics, holds 5.36M shares in TScan Therapeutics (Ticker: TCRX), holds 8.88M shares in Passage Bio (Ticker: PASG). Most recently, Lynx1 Capital Management LP Bought ― shares of TScan Therapeutics on Dec 16, 2024 for an estimated value of 385.40K.
Lynx1 Capital Management LP TScan Therapeutics (TCRX)Ten Percent Owner
TScan Therapeutics (TCRX)
Ten Percent Owner
Ranked #90,893 out of 99,797 Corporate Insiders
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
-60.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Lynx1 Capital Management LP holds in companies
Most Profitable Insider Trade
The most profitable trade made by Lynx1 Capital Management LP
Lynx1 Capital Management LP's Trading History
TScan Therapeutics
Dec 16, 2024
Ten Percent Owner
Informative Buy
385.40K
$15.91M
Passage Bio
Nov 27, 2024
Ten Percent Owner
Informative Buy
282.17K
$5.86M
List of latest transactions for each holding click on a transaction to see Lynx1 Capital Management LP's performance on stock
You May Also Like
Lynx1 Capital Management LP insider profile FAQ
What is the percentage of profitable transactions made by Lynx1 Capital Management LP?
The percentage of profitable transactions made by Lynx1 Capital Management LP is 67%.
What is the average return per transaction made by Lynx1 Capital Management LP?
The average return per transaction made by Lynx1 Capital Management LP is -60.40%.
What stocks does Lynx1 Capital Management LP hold?
Lynx1 Capital Management LP holds: TCRX, PASG stocks.
What was Lynx1 Capital Management LP’s latest transaction?
Lynx1 Capital Management LP latest transaction was an Informative Buy of $385.40K.
What was Lynx1 Capital Management LP's most profitable transaction?
Lynx1 Capital Management LP’s most profitable transaction was an Informative Buy of PASG stock on November 27, 2024. The return on the trade was 16.30%.
What is Lynx1 Capital Management LP's role in TScan Therapeutics?
Lynx1 Capital Management LP's role in TScan Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.